Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. We specifically apply our approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene driver mutations or synthetic lethal contexts. Leveraging our unique patient selection platform, Acrivon Therapeutics aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials. Acrivon Therapeutics and its clinical biomarker development group is headquartered in the greater Boston area, with biomarker discovery efforts concentrated in our wholly-owned subsidiary in Lund, Sweden.
View Top Employees from Acrivon Therapeutics, Inc.Website | https://acrivon.com |
Employees | 64 (47 on RocketReach) |
Founded | 2018 |
Address | 700 North Main Street, Cambridge, Massachusetts 02139, US |
Technologies |
JavaScript,
HTML,
PHP
+12 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Science and Engineering, Drug Discovery |
Looking for a particular Acrivon Therapeutics, Inc. employee's phone or email?
Rasmus Holm-Jorgensen is the CFO of Acrivon Therapeutics, Inc..
47 people are employed at Acrivon Therapeutics, Inc..
Acrivon Therapeutics, Inc. is based in Cambridge, Massachusetts.